10 powodów, dla których warto zastosować peryndopryl w leczeniu nadciśnienia tętniczego Artykuł przeglądowy

##plugins.themes.bootstrap3.article.main##

Justyna Pordzik
Marek Postuła

Abstrakt

Inhibitory enzymu konwertującego angiotensynę (ACE) stanowią heterogenną grupę leków, która różni się wpływem klinicznym na pacjenta wynikającym z różnic dotyczących lipofilności, wiązania z tkankowym ACE, czasem działania, okresu połowicznego rozpadu oraz wpływu na stężenie bradykininy. Spośród inhibitorów ACE peryndopryl cechuje się unikalnymi właściwościami plejotropowymi, które są związane z selektywnością w stosunku do miejsc wiążących bradykininę oraz działaniem na syntezę tlenku azotu i apoptozę komórek śródbłonka.

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.themes.bootstrap3.article.details##

Jak cytować
Pordzik , J., & Postuła , M. (2017). 10 powodów, dla których warto zastosować peryndopryl w leczeniu nadciśnienia tętniczego . Kardiologia W Praktyce, 11(1), 8-11. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1254
Dział
Artykuły

Bibliografia

1. Unger T., Ganten D., Lang R.E.: Tissue converting enzyme and cardiovascular actions of converting enzyme inhibitors. J. Cardiovasc. Pharmacol. 1986; 8(supl. 10): S75-S81.
2. Zhuo J.L., Mendelsohn F.A., Ohishi M.: Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002; 39(2 pt 2): 634-638.
3. Ferrari R.: Preserving bradykinin or blocking angiotensin II: the cardiovascular dilemma. Dialogues Cardiovasc. Med. 2004; 9(2): 71-89.
4. Morgan T., Anderson A.: Clinical efficacy of perindopril in hypertension. Clin. Exp. Pharmacol. Physiol. Suppl. 1992; 19: 61-65.
5. Farnsworth A.: Angiotensin-converting enzyme inhibitors in heart failure: target dose prescription in elderly patients. Age Ageing. 1998; 27(5): 653-654.
6. Ceconi C., Francolini G., Olivares A. et al.: Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur. J. Pharmacol. 2007; 577(1-3): 1-6.
7. Watanabe K., Saito Y., Ma M. et al.: Comparative effects of perindopril with enalapril in rats with dilated cardiomyopathy. J. Cardiovasc. Pharm. 2003; 42(supl. 1): S105-S109.
8. Vítovec J., Spinar J.: First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril. Slovak Investigator Group. Eur. J. Heart Fail. 2000; 2(3): 299-304.
9. MacFadyen R.J., Lees K.R., Reid J.L.: Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study. Br. Heart J. 1991; 66(3): 206-211.
10. Cushman D.W., Cheung H.S.: Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochim. Biophys. Acta Oct. 1971; 250(1): 261-265.
11. Dzau V.J., Bernstein K., Celermajer D. et al.: The relevance of tissue angiotensin converting enzyme: manifestations in mechanistic and endpoint data. Am. J. Cardiol. 2001; 88(9A): 1L-20L.
12. Fabris B., Chen B.Z., Pupic V. et al.: Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue. J. Cardiovasc. Pharmacol. 1990; 15(supl. 2): S6-S13.
13. Ranadive S.A., Chen A.X., Serajuddin A.T.: Relative lipophilicities and structural pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm. Res. Nov. 1992; 9(11): 1480-1486.
14. Johnston C.I.: Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension 1994; 23(2): 258-268.
15. Burris J.F.: The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension. J. Clin. Pharmacol. 1995; 35(4): 337-342.
16. Lala A., McLaughlin M.A.: Do ACE inhibitors all provide the same outcomes benefits in high-risk cardiovascular patients? Curr. Hypertens. Rep. 2008; 10(4): 286-292.
17. Ceconi C., Francolini G., Bastianon D. et al.: Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc. Drugs. Ther. 2007; 21(6): 423-429.
18. Watanabe K., Saito Y., Ma M. et al.: Comparative effects of perindopril with enalapril in rats with dilated cardiomyopathy. J. Cardiovasc. Pharm. 2003; 42(supl. 1): S105-S109.
19. Pilote L., Abrahamowicz M., Rodrigues E. et al.: Mortality rates in elderly patients who take different angiotensin converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann. Int. Med. 2004; 141(2): 102-112.
20. Comini L., Bachetti T., Cargnoni A. et al.: Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. Pharmacological Res. 2007; 56(1): 42-48.
21. Krysiak R., Sierant M., Marek B., Okopien B.: The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease. Endokrynologia Polska 2010; 61(6): 683-690.
22. Krysiak R., Okopien B.: Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol. Rep. 2008; 60(4): 514-523.
23. Brugts J.J., Ninomiya T., Boersma E. et al.: The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur. Heart J. 2009; 30(11): 1385-1394.
24. Pilote L., Abrahamowicz M., Eisenberg M. et al.: Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ 2008; 178(10): 1303-1311.
25. Alderman C.P.: Adverse effects of the angiotensin-converting enzyme inhibitors. Ann. Pharmacother. 1996; 30(1): 55-61.
26. Fox K.M.: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362(9386): 782-788.
27. Yusuf S., Sleight P., Pogue J. et al.: Effects of an angiotensin-converting enzyme inhibitor, ramipryl, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000; 342(3): 145-153.
28. PROGRESS Collaborative Group. Randomised trial of a perindopril based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033-1041.
29. Ceconi C., Fox K.M., Remme W.J. et al.: ACE-inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc. Res. 2007; 73(1): 237-246.
30. Cargnoni A., Comini L., Bernocchi P. et al.: Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril. British J. Pharm. 2001; 133(1): 145-153.
31. du Toit E.F., Genade S., Carlini S. et al.: Efficacy of ischaemic preconditioning in the eNOS overexpressed working mouse heart model. Eur. J. Pharmacol. 2007; 556(1-3): 115-120.
32. Cleland J.G., Tendera M., Adamus J. et al.: The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur. Heart J. 2006; 27: 2338-2345.
33. Masuell M., Brusca G., Pardo A. et al.: ACE inhibitors in heart failure – switching from enalapril to perindopril. Curr. Med. Res. Opin. 2002; 18(5): 296-302.